SCHEMBL2397461

SCHEMBL2397461

O=C(O)C(F)(F)c1ccccc1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
SLC13A5 Q86YT5 1/20 0.44
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.42
BCAT2 O15382 1/20 0.42
BCL2L1 Q07817 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MME P08473 1/20 0.40
HNF4A P41235 1/20 0.40
HDAC6 Q9UBN7 3/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
PLK1 P53350 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890660 0.85 PDK2 (0.43) ALDH1A1PPARGPLK1
SCHEMBL2393825 0.85 BCAT2 (0.48) ALDH1A1HPGDSLC13A5PPARGPPARA
SCHEMBL9890661 0.84 PDK2 (0.45) KMT2AMEN1
SCHEMBL13199346 0.83 CES1 (0.46) ALDH1A1HPGDPPARGCYP2C9SMN1; SMN2
SCHEMBL2393250 0.81 AKR1C3 (0.46) ALDH1A1HPGDPPARGPPARAKMT2A
SCHEMBL9890796 0.80 PLK1 (0.48) ALDH1A1HPGDSLC13A5PPARGPPARA
SCHEMBL28846137 0.80 KCNN4 (0.44) ALDH1A1HPGDPPARGPPARAFFAR4
Urea SCHEMBL27881390 0.78 FFAR4 (0.54) ALDH1A1HPGDSLC13A5PPARGPPARA
SCHEMBL17420697 0.77 ALDH1A1 (0.49) ALDH1A1HPGDPPARG
SCHEMBL2394924 0.77 POLB (0.46) ALDH1A1HPGDPPARGPPARAFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885HPGD 3524/4885SLC13A5 579/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885HPGD 3524/4885SLC13A5 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.